Pharma Mar, trading on the OTC Markets under the symbol PHMMF, is a Spain-based biopharmaceutical company specializing in the discovery and development of innovative oncology therapies derived from marine resources. Founded in 1986 as a subsidiary of the Zeltia group, Pharma Mar has leveraged its proprietary marine biodiscovery platform to identify natural compounds with anticancer potential. Over the years, the company has built a robust pipeline that spans clinical and preclinical stages, focusing on both small‐molecule drugs and RNA‐based therapeutics.
The company’s flagship products include Yondelis (trabectedin), approved in Europe for the treatment of soft tissue sarcoma and relapsed ovarian cancer, and Zepzelca (lurbinectedin), marketed in the United States for small cell lung cancer. In addition, Pharma Mar has advanced plitidepsin (Aplidin) through late‐stage trials, targeting multiple myeloma and exploring antiviral properties. Beyond its lead compounds, the firm is actively investigating immuno‐oncology candidates and CAR‐T cell platforms, reflecting a strategic expansion into next‐generation cancer therapies.
Headquartered in Colmenar Viejo, Madrid, Pharma Mar maintains research and manufacturing facilities in Spain, with collaborations and regulatory filings across Europe, North America and Asia. The company’s global footprint is supported by partnerships with major pharmaceutical firms for marketing and distribution, enabling broader patient access and shared development resources. Its R&D operations benefit from state‐of‐the‐art laboratories and marine bioprospecting vessels dedicated to discovering novel compounds in diverse ocean environments.
Leadership at Pharma Mar is steered by its founder and Chairman, José María Fernández Sousa‐Faro, whose vision has driven the company’s marine‐based research ethos. Supported by a management team with extensive experience in oncology drug development and regulatory affairs, Pharma Mar remains committed to translating marine biodiversity into effective cancer treatments. The firm’s strategic focus on therapeutic innovation and global collaboration positions it as a notable player in the biopharmaceutical landscape.
AI Generated. May Contain Errors.
